BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

PRR11 and SKA2 gene pair is overexpressed and regulated by p53 in breast cancer

  • Wang, Yitao (Department of Biochemistry and Molecular Biology, Chongqing Medical University) ;
  • Zhang, Chunxue (Laboratory of Birth Defects and Related Diseases of Women and Children, West China Second University Hospital, Sichuan University) ;
  • Mai, Li (Department of Clinical Laboratory, The Second Affiliated Hospital, Chongqing Medical University) ;
  • Niu, Yulong (Department of Biochemistry and Molecular Biology, Chongqing Medical University) ;
  • Wang, Yingxiong (Laboratory of Reproductive Biology, School of Public Health, Chongqing Medical University) ;
  • Bu, Youquan (Department of Biochemistry and Molecular Biology, Chongqing Medical University)
  • Received : 2018.09.07
  • Accepted : 2018.12.31
  • Published : 2019.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Our previous study found that two novel cancer-related genes, PRR11 and SKA2, constituted a classic gene pair that was regulated by p53 and NF-Y in lung cancer. However, their role and regulatory mechanism in breast cancer remain elusive. In this study, we found that the expression levels of PRR11 and SKA2 were upregulated and have a negative prognotic value in breast cancer. Loss-of-function experiments showed that RNAi-mediated knockdown of PRR11 and/or SKA2 inhibited proliferation, migration, and invasion of breast cancer cells. Mechanistic experiments revealed that knockdown of PRR11 and/or SKA2 caused dysregulation of several downstream genes, including CDK6, TPM3, and USP12, etc. Luciferase reporter assays demonstrated that wild type p53 significantly repressed the PRR11-SKA2 bidirectional promoter activity, but not NF-Y. Interestingly, NF-Y was only essential for and correlated with the expression of PRR11, but not SKA2. Consistently, adriamycin-induced (ADR) activation of endogenous p53 also caused significant repression of the PRR11 and SKA2 gene pair expression. Notably, breast cancer patients with lower expression levels of either PRR11 or SKA2, along with wild type p53, exhibited better disease-free survival compared to others with p53 mutations and/or higher expression levels of either PRR11 or SKA2. Collectively, our study indicates that the PRR11 and SKA2 transcription unit might be an oncogenic contributor and might serve as a novel diagnostic and therapeutic target in breast cancer.

Keywords

References

  1. Siegel RL, Miller KD and Jemal A (2018) Cancer statistics, 2018: Cancer Statistics, 2018. CA Cancer J Clin 68, 7-30 https://doi.org/10.3322/caac.21442
  2. Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015: Cancer Statistics in China, 2015. CA Cancer J Clin 66, 115-132 https://doi.org/10.3322/caac.21338
  3. Trinklein ND (2003) An Abundance of Bidirectional Promoters in the Human Genome. Genome Res 14 62-66 https://doi.org/10.1101/gr.1982804
  4. Ji Y, Xie M, Lan H et al (2013) PRR11 is a novel gene implicated in cell cycle progression and lung cancer. Int J Biochem Cell Biol 45, 645-656 https://doi.org/10.1016/j.biocel.2012.12.002
  5. Song Z, Liu W, Xiao Y et al (2015) PRR11 Is a Prognostic Marker and Potential Oncogene in Patients with Gastric Cancer. PLoS One 10, e0128943 https://doi.org/10.1371/journal.pone.0128943
  6. Chen Y, Cha Z, Fang W et al (2015) The prognostic potential and oncogenic effects of PRR11 expression in hilar cholangiocarcinoma. Oncotarget 6, 20419-20433 https://doi.org/10.18632/oncotarget.3983
  7. Zhang C, Zhang Y, Li Y et al (2015) PRR11 regulates late-S to G2/M phase progression and induces premature chromatin condensation (PCC). Biochem Biophys Res Commun 458, 501-508 https://doi.org/10.1016/j.bbrc.2015.01.139
  8. Chan YW, Jeyaprakash AA, Nigg EA and Santamaria A (2012) Aurora B controls kinetochore-microtubule attachments by inhibiting Ska complex-KMN network interaction. J Cell Biol 196, 563-571 https://doi.org/10.1083/jcb.201109001
  9. Guimaraes GJ and DeLuca JG (2009) Connecting with Ska, a key complex at the kinetochore-microtubule interface. EMBO J 28, 1375-1377 https://doi.org/10.1038/emboj.2009.124
  10. Zhang Q, Sivakumar S, Chen Y et al (2017) Ska3 Phosphorylated by Cdk1 Binds Ndc80 and Recruits Ska to Kinetochores to Promote Mitotic Progression. Curr Biol 27, 1477-1484.e4 https://doi.org/10.1016/j.cub.2017.03.060
  11. Jeyaprakash AA, Santamaria A, Jayachandran U et al (2012) Structural and functional organization of the Ska complex, a key component of the kinetochore-microtubule interface. Mol Cell 46, 274-286 https://doi.org/10.1016/j.molcel.2012.03.005
  12. Welburn JPI, Grishchuk EL, Backer CB et al (2009) The human kinetochore Ska1 complex facilitates microtubule depolymerization-coupled motility. Dev Cell 16, 374-385 https://doi.org/10.1016/j.devcel.2009.01.011
  13. Gaitanos TN, Santamaria A, Jeyaprakash AA, Wang B, Conti E, Nigg EA (2009) Stable kinetochore-microtubule interactions depend on the Ska complex and its new component Ska3/C13Orf3. EMBO J 28, 1442-1452 https://doi.org/10.1038/emboj.2009.96
  14. Hanisch A, Sillje HH, and Nigg EA (2006) Timely anaphase onset requires a novel spindle and kinetochore complex comprising Ska1 and Ska2. EMBO J 25, 5504-5515 https://doi.org/10.1038/sj.emboj.7601426
  15. Rice L, Waters CE, Eccles J et al (2008) Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. J Endocrinol 198, 499-509 https://doi.org/10.1677/JOE-08-0019
  16. Wang Y, Zhang Y, Zhang C et al (2015) The gene pair PRR11 and SKA2 shares a NF-Y-regulated bidirectional promoter and contributes to lung cancer development. Biochim Biophys Acta BBA - Gene Regul Mech 1849, 1133-1144 https://doi.org/10.1016/j.bbagrm.2015.07.002
  17. Wang Y, Weng H, Zhang Y et al (2017) The PRR11-SKA2 bidirectional transcription unit is negatively regulated by p53 through NF-Y in lung cancer cells. Int J Mol Sci 18, 534 https://doi.org/10.3390/ijms18030534
  18. Zhang L (2018) Silencing of PRR11 suppresses cell proliferation and induces autophagy in NSCLC cells. Genes Dis 5, 158-166 https://doi.org/10.1016/j.gendis.2017.12.003
  19. Chaudhary S, Madhukrishna B, Adhya AK, Keshari S and Mishra SK (2016) Overexpression of caspase 7 is ERalpha dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip). Oncogenesis 5, e219 https://doi.org/10.1038/oncsis.2016.12
  20. Murphy CG and Dickler MN (2015) The Role of CDK4/6 inhibition in breast cancer. Oncologist 20, 483-490 https://doi.org/10.1634/theoncologist.2014-0443
  21. Wang L, Zhan X, Shen X et al (2018) P16 promotes the growth and mobility potential of breast cancer both in vitro and in vivo: the key role of the activation of IL-6/JAK2/STAT3 signaling. Mol Cell Biochem 446, 137-148 https://doi.org/10.1007/s11010-018-3281-4
  22. Selander KS, Li L, Watson L et al (2004) Inhibition of gp130 signaling in breast cancer blocks constitutive activation of Stat3 and inhibits in vivo malignancy. Cancer Res 64, 6924-6933 https://doi.org/10.1158/0008-5472.CAN-03-2516
  23. Niki T, Izumi S, Saegusa Y et al (2000) MSSP promotes ras/myc cooperative cell transforming activity by binding to c-Myc. Genes Cells Devoted Mol Cell Mech 5, 127-141 https://doi.org/10.1046/j.1365-2443.2000.00311.x
  24. Lange AM and Lo H-W (2018) Inhibiting TRK Proteins in clinical cancer therapy Cancers 10, 105 https://doi.org/10.3390/cancers10040105
  25. Lehmann BD and Pietenpol JA (2012) Targeting mutant p53 in human tumors. J Clin Oncol Off J Am Soc Clin Oncol 30, 3648-3650 https://doi.org/10.1200/JCO.2012.44.0412
  26. Nguyen D, Liao W, Zeng SX and Lu H (2017) Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther 178, 92-108 https://doi.org/10.1016/j.pharmthera.2017.03.013
  27. Miller L, Smeds J, George JD et al (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 102, 13550-13555 https://doi.org/10.1073/pnas.0506230102
  28. Gyorffy B, Lanczky A, Eklund AC et al (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123, 725-731 https://doi.org/10.1007/s10549-009-0674-9